

Synthesis of S^2 -Alkyl-2-thiouridines

Adel A.-H. Abdel-Rahman,^a Magdy A. Zahran,^a Ahmed E.-S. Abdel-Megied,^a Erik B. Pedersen,^{*a} Claus Nielsen^b

^a Department of Chemistry, Odense University, Campusvej 55, DK-5230 Odense M, Denmark

^b Retrovirus Laboratory, Department of Virology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen, Denmark

Fax +4566158780; E-mail EBP@OUKEMI.OU.DK

Received 1 June 1995; revised 3 September 1995


5-Substituted S^2 -alkyl-2-thiouracils **1a-i** were treated with 1,1,1,3,3,3-hexamethyldisilazane and ammonium sulfate at reflux temperature and condensed with 1,2,3,5-tetra-*O*-acetyl- β -D-ribofuranose in acetonitrile using trimethylsilyl trifluoromethanesulfonate as a catalyst to afford the corresponding protected nucleosides **2a-i** which were deprotected with saturated ammonia in methanol. When the nucleobase was substituted with ethoxycarbonyl or cyano groups in the 5-position or was unsubstituted, the deprotection reaction of the nucleoside also resulted in replacement of the methylthio group. This was not observed with 5-alkyl and 5-methoxy substituents.

Singer et al.¹ reported that O^2 -ethyl and O^4 -methyl derivatives of uridine 5'-diphosphate (UDP) could be copolymerized with UDP or cytidine 5'-diphosphate (CDP), using polynucleotide phosphorylase. These copolymers were used as templates for DNA dependent RNA polymerase in the presence of Mn^{2+} . O^2 -Alkylation of uracil (U) or thymine (T) is, in contrast to O^4 -alkylation, a relatively frequent result of treatment of double-stranded nucleic acids with *N*-nitroso alkylating agents. In single-stranded nucleic acids both O^2 - and O^4 -alkylation of U may be involved in the high carcinogenicity of these alkylating agents.²⁻⁶


The reaction of nucleic acids with carcinogens of *N*-nitroso type showed that O^2 -alkylpyrimidines were the major products.⁵ Only a few examples of the corresponding S^2 -alkylated 2-thiouridines have been reported⁷⁻⁹ and they were typically prepared by alkylation of the corresponding 2-thio nucleoside. We thought that such compounds could be synthesized in a more straightforward manner by condensing S^2 -alkylated 2-thiouracils with appropriate sugar derivatives. Considering the interest in O^2 -methyl nucleosides in conjunction with DNA as mentioned above, we focused this work on the synthesis of S^2 -alkylated 2-thiouridine derivatives.

In the present investigation we have synthesized S^2 -methyl as well as the S^2 -ethyl-2-thiouracils **1** by alkylation of the appropriate 2-thiouracils according to the procedure of Brown et al.¹⁰ and treated them according to the procedure of Wittenburg¹¹ with 1,1,1,3,3,3-hexamethyldisilazane and ammonium sulfate at reflux temperature in order to obtain the silylated derivatives which were condensed with 1,2,3,5-tetra-*O*-acetyl- β -D-ribofuranose in dry acetonitrile using trimethylsilyl trifluoromethanesulfonate as the catalyst according to the method of Vorbrüggen et al.¹² After chromatographic purification the β -anomers **2a-i** were obtained in 61–93% yield. Deprotection of the hydroxy groups in the nucleosides **2a-g** with ammonia in methanol afforded the corresponding S^2 -alkyl-2-thiouridine derivatives **3a-g** in 40–96% yield after chromatographic purification.

The methylthio group was very susceptible to a nucleophilic substitution reaction and was in some cases replaced by a methoxy group. On deprotection of **2a** we



Scheme 1



Scheme 2

obtained **3a** in 40% yield together with **4** in 34% yield. When deprotection of **2a** was performed with sodium methoxide in methanol, we only isolated the O^2 -methylated compound **4** in 43% yield. Substitution of the meth-

Table 1. Yields and Physical Data of the New Compounds Prepared

Compound	Yield (%)	mp (°C)	$[\alpha]_D^{25}$ ^a	Molecular Formula ^b	MS m/z (%)
2a	93				
2b	90				
2c	91				
2d	85				
2e	76				
2f	93				429 (M + H ⁺) ^c
2g	91				445 (M + H ⁺) ^c
2h	61				
2i	70				
3a	40	152–153		C ₁₀ H ₁₄ N ₂ O ₅ S (274.3)	274 (M ⁺ , 0.4)
3b	86	204–205	+ 25.73	C ₁₁ H ₁₆ N ₂ O ₅ S (288.3)	288 (M ⁺ , 0.7)
3c	95	202–203	+ 33.33	C ₁₂ H ₁₈ N ₂ O ₅ S · 0.5H ₂ O (311.4)	302 (M ⁺ , 2)
3d	85	183–184		C ₁₃ H ₂₀ N ₂ O ₅ S (316.3)	316 (M ⁺ , 3)
3e	80	132–134	+ 35.59	C ₁₇ H ₂₀ N ₂ O ₅ S (364.1093)	364 (M ⁺ , 0.7)
3f	73	232–233	+ 24.33	C ₁₂ H ₁₈ N ₂ O ₅ S (302.4)	302 (M ⁺ , 0.7)
3g	77			C ₁₂ H ₁₈ N ₂ O ₆ S (318.4)	318 (M ⁺ , 0.05)

^a Specific rotation (**3b**, **c**, **3e**, **f**) was measured in MeOH; $c = 1$.^b The microanalyses (**3a–3d**, **3f–3g**) or HRMS (**3e**) data were in satisfactory agreement with the calculated values: C ± 0.44 , H ± 0.32 , N ± 0.45 ; $m/z \pm 0.0004$ (M⁺).^c FAB MS (**2f**, **g**) was measured in DMSO + 3-nitrobenzyl alcohol.**Table 2.** NMR Data of the New Compounds Prepared

Compound	¹ H NMR (DMSO- <i>d</i> ₆ /TMS) δ , J (Hz)	¹³ C NMR (DMSO- <i>d</i> ₆ /TMS) δ
2a	2.07 (s, 6H, 2 × COCH ₃), 2.11 (s, 3H, COCH ₃), 2.51 (s, 3H, SCH ₃), 4.34 (d, 2H, $J = 4.1$, 5'-H), 4.41 (m, 1H, 4'-H), 5.31 (t, 1H, $J = 6.1$, 3'-H), 5.43 (t, 1H, $J = 6.1$, 2'-H), 5.97 (d, 1H, $J = 5.7$, 1'-H), 6.05 (d, 1H, $J = 7.8$, 5-H), 7.88 (d, 1H, $J = 7.7$, 6-H)	14.20 (SCH ₃), 19.95, 20.15, 20.37 (3 × COCH ₃), 62.68 (C-5'), 69.26 (C-3'), 72.07 (C-2'), 79.76 (C-4'), 88.92 (C-1'), 109.31 (C-5), 138.95 (C-6), 161.86 (C-2), 165.92 (C-4), 168.94, 169.20, 169.82 (3 × COCH ₃)
2b	1.86 (s, 3H, 5-CH ₃), 2.07 (s, 3H, COCH ₃), 2.08 (s, 3H, COCH ₃), 2.11 (s, 3H, COCH ₃), 2.51 (s, 3H, SCH ₃), 4.38 (m, 3H, 4'-H, 5'-H), 5.33 (m, 1H, 3'-H), 5.43 (t, 1H, $J = 6.2$, 2'-H), 5.96 (d, 1H, $J = 5.9$, 1'-H), 7.78 (s, 1H, 6-H)	13.22 (SCH ₃), 14.26 (5-CH ₃), 19.97, 20.16, 20.39 (3 × COCH ₃), 62.70 (C-5'), 69.21 (C-3'), 72.04 (C-2'), 79.71 (C-4'), 88.90 (C-1'), 117.85 (C-5), 134.81 (C-6), 160.80 (C-2), 167.00 (C-4), 168.94, 169.21, 169.82 (3 × COCH ₃)
2c	1.17 (t, 3H, $J = 7.3$, CH ₂ CH ₃), 2.11 (s, 3H, COCH ₃), 2.15 (s, 3H, COCH ₃), 2.18 (s, 3H, COCH ₃), 2.44 (q, 2H, $J = 7.3$, CH ₂ CH ₃), 2.62 (s, 3H, SCH ₃), 4.33 (d, 1H, $J = 12.2$, 5'-H), 4.40 (br s, 1H, 4'-H), 4.44 (dd, 1H, $J = 12.5$, 2.9, 5'-H), 5.31 (m, 2H, 2'-H, 3'-H), 6.06 (d, 1H, $J = 4.9$, 1'-H), 7.37 (s, 1H, 6-H)	12.04 (CH ₂ CH ₃), 14.77 (SCH ₃), 20.12, 20.21, 20.31 (3 × COCH ₃), 21.20 (CH ₂ CH ₃), 62.82 (C-5'), 69.84 (C-3'), 72.82 (C-2'), 80.44 (C-4'), 88.35 (C-1'), 124.74 (C-5), 131.82 (C-6), 161.21, (C-2), 167.87 (C-4), 168.90, 169.32, 169.72 (3 × COCH ₃)
2d	0.87 (t, 3H, $J = 7.2$, CH ₃), 1.48 (hexet, 2H, $J = 7.3$, CH ₂), 2.06 (s, 3H, COCH ₃), 2.08 (s, 3H, COCH ₃), 2.11 (s, 3H, COCH ₃), 2.25 (t, 2H, $J = 7.8$, CH ₂), 2.51 (s, 3H, SCH ₃), 4.38 (m, 3H, 4'-H, 5'-H), 5.35 (m, 1H, 3'-H), 5.46 (t, 1H, $J = 6.2$, 2'-H), 5.96 (d, 1H, $J = 6.2$, 1'-H), 7.67 (s, 1H, 6-H)	13.34 (CH ₃), 14.24 (SCH ₃), 19.94, 20.15, 20.35 (3 × COCH ₃), 20.80 (CH ₂), 29.28 (CH ₂), 62.72 (C-5'), 69.31 (C-3'), 71.90 (C-2'), 79.80 (C-4'), 88.85 (C-1'), 121.54 (C-5), 134.69 (C-6), 160.66 (C-2), 166.45 (C-4), 168.91, 169.21, 169.76 (3 × COCH ₃)
2e	1.96 (s, 3H, COCH ₃), 2.08 (s, 3H, COCH ₃), 2.12 (s, 3H, COCH ₃), 2.61 (s, 3H, SCH ₃), 3.74 (d, 1H, $J = 16.3$, CH ₂), 3.77 (d, 1H, $J = 16.3$, CH ₂), 4.03 (dd, 1H, $J = 12.4$, 2.6, 5'-H), 4.22 (dd, 1H, $J = 12.4$, 4.0, 5'-H), 4.31 (m, 1H, 4'-H), 5.15 (m, 2H, 2'-H, 3'-H), 6.01 (d, 1H, $J = 5.3$, 1'-H), 7.21–7.32 (m, 6H, H _{arom} , 6-H)	14.71 (SCH ₃), 20.01, 20.19, 20.34 (3 × COCH ₃), 33.48 (CH ₂), 62.73 (C-5'), 69.97 (C-3'), 72.74 (C-2'), 80.30 (C-4'), 88.47 (C-1'), 123.00 (C-5), 126.46, 128.34, 128.88 (C _{arom}), 133.68 (C-6), 137.71 (C _{arom}), 161.33 (C-2), 167.51 (C-4), 168.71, 169.10, 169.54 (3 × COCH ₃)
2f	1.28 (t, 3H, $J = 7.5$, SCH ₂ CH ₃), 1.86 (s, 3H, CH ₃), 2.06 (s, 3H, COCH ₃), 2.08 (s, 3H, COCH ₃), 2.11 (s, 3H, COCH ₃), 3.14 (q, 2H, $J = 7.5$, SCH ₂), 4.36 (m, 3H, 4'-H, 5'-H), 5.32 (d, 1H, $J = 2.5$, 3'-H), 5.42 (m, 1H, 2'-H), 5.93 (d, 1H, $J = 5.0$, 1'-H), 7.77 (s, 1H, 6-H)	13.25 (5-CH ₃), 13.96 (SCH ₂ CH ₃), 19.96, 20.16, 20.39 (3 × COCH ₃), 25.74 (SCH ₂), 62.71 (C-5'), 69.26 (C-3'), 71.99 (C-2'), 79.74 (C-4'), 88.75 (C-1'), 117.98 (C-5), 134.86 (C-6), 160.07 (C-2), 167.02 (C-4), 168.92, 169.23, 169.81 (3 × COCH ₃)

Table. (continued)


Compound	^1H NMR (DMSO- d_6 /TMS) δ , J (Hz)	^{13}C NMR (DMSO- d_6 /TMS) δ
2g	1.27 (t, 3 H, $J = 7.5$, SCH_2CH_3), 2.05, 2.07, 2.11 ($3 \times$ s, 9 H, $3 \times \text{COCH}_3$), 3.12 (q, 2 H, $J = 7.5$, SCH_2), 3.70 (s, 3 H, OCH_3), 4.42 (s, 3 H, 4'-H, 5'-H), 5.32 (m, 1 H, 3'-H), 5.51 (t, 1 H, $J = 7.5$, 2'-H), 6.00 (d, 1 H, $J = 7.5$, 1'-H), 7.35 (s, 1 H, 6-H)	14.04 (SCH_2CH_3), 19.97, 20.20, 20.39 ($3 \times \text{COCH}_3$), 26.00 (SCH_2), 55.95 (OCH_3), 62.74 (C-5'), 69.24 (C-3'), 71.75 (C-2'), 80.07 (C-4'), 88.94 (C-1'), 117.81 (C-5), 142.06 (C-6), 157.01 (C-2), 161.69 (C-4), 168.90, 169.27, 169.87 ($3 \times \text{COCH}_3$)
2h	1.23 (t, 3 H, $J = 6.9$, CH_3), 2.05 (s, 3 H, COCH_3), 2.08 (s, 3 H, COCH_3), 2.09 (s, 3 H, COCH_3), 2.52 (s, 3 H, SCH_3), 4.21 (m, 2 H, 5'-H), 4.35 (m, 2 H, CH_2), 4.46 (m, 1 H, 4'-H), 5.34 (t, 1 H, $J = 6.1$, 3'-H), 5.46 (t, 1 H, $J = 5.8$, 2'-H), 6.00 (d, 1 H, $J = 5.6$, 1'-H), 8.40 (s, 1 H, 6-H)	13.96 (CH_3), 14.62 (SCH_3), 20.07, 20.24, 20.33 ($3 \times \text{COCH}_3$), 60.63 (OCH_2), 62.61 (C-5'), 69.37 (C-3'), 72.87 (C-2'), 80.40 (C-4'), 89.26 (C-1'), 111.49 (C-5), 143.48 (C-6), 161.60 (C-2), 161.80 (C-4), 163.60 (COOEt), 169.03, 169.23, 169.91 ($3 \times \text{COCH}_3$)
2i	2.07 (s, 3 H, COCH_3), 2.08 (s, 3 H, COCH_3), 2.10 (s, 3 H, COCH_3), 2.54 (s, 3 H, SCH_3), 4.39 (m, 3 H, 4'-H, 5'-H), 5.35 (t, 1 H, $J = 6.0$, 3'-H), 5.51 (t, 1 H, $J = 4.5$, 2'-H), 6.02 (d, 1 H, $J = 4.2$, 1'-H), 8.72 (s, 1 H, 6-H)	14.75 (SCH_3), 20.04, 20.15, 20.44 ($3 \times \text{COCH}_3$), 62.30 (C-5'), 68.30 (C-3'), 72.89 (C-2'), 79.79 (C-4'), 90.00 (C-1'), 95.57 (CN), 114.54 (C-5), 147.87 (C-6), 161.99 (C-2), 163.89 (C-4), 168.93, 169.04, 169.85 ($3 \times \text{COCH}_3$)
3a	2.48 (s, 3 H, SCH_3), 3.61 (m, 2 H, 5'-H), 3.94 (m, 1 H, 4'-H), 4.01 (m, 1 H, 3'-H), 4.11 (q, 1 H, $J = 5.2$, 2'-H), 5.23 (m, 2 H, 3'-OH, 5'-OH), 5.58 (d, 1 H, $J = 5.9$, 2'-OH), 5.70 (d, 1 H, $J = 5.3$, 1'-H), 5.95 (d, 1 H, $J = 7.7$, 5-H), 8.08 (d, 1 H, $J = 7.8$, 6-H)	14.07 (SCH_3), 60.60 (C-5'), 69.86 (C-3'), 74.52 (C-2'), 85.81 (C-4'), 91.31 (C-1'), 108.73 (C-5), 139.16 (C-6), 162.28 (C-2), 166.53 (C-4)
3b	1.84 (s, 3 H, CH_3), 2.50 (s, 3 H, SCH_3), 3.66 (m, 2 H, 5'-H), 3.96 (m, 1 H, 4'-H), 4.06 (m, 1 H, 3'-H), 4.14 (m, 1 H, 2'-H), 5.30 (m, 2 H, 3'-OH, 5'-OH), 5.62 (d, 1 H, $J = 5.7$, 2'-OH), 5.70 (d, 1 H, $J = 5.3$, 1'-H), 8.02 (s, 1 H, 6-H)	13.46 (CH_3), 14.21 (SCH_3), 60.71 (C-5'), 69.91 (C-3'), 73.43 (C-2'), 85.82 (C-4'), 91.31 (C-1'), 117.24 (C-5), 135.39 (C-6), 161.21 (C-2), 167.74 (C-4)
3c	1.05 (t, 3 H, $J = 7.4$, CH_3), 2.26 (q, 2 H, $J = 7.4$, CH_2), 2.49 (s, 3 H, SCH_3), 3.65 (m, 2 H, 5'-H), 3.96 (m, 1 H, 4'-H), 4.04 (q, 1 H, $J = 4.1$, 3'-H), 4.14 (q, 1 H, $J = 5.3$, 2'-H), 5.26 (m, 2 H, 3'-OH, 5'-OH), 5.60 (d, 1 H, $J = 5.8$, 2'-OH), 5.70 (d, 1 H, $J = 5.3$, 1'-H), 8.01 (s, 1 H, 6-H)	12.11 (CH_3), 14.19 (SCH_3), 20.59 (CH_2), 60.59 (C-5'), 69.96 (C-3'), 74.66 (C-2'), 85.79 (C-4'), 91.47 (C-1'), 122.66 (C-5), 134.53 (C-6), 160.87 (C-2), 167.13 (C-4)
3d	0.86 (t, 3 H, $J = 7.2$, CH_3), 1.48 (hextet, 2 H, $J = 7.2$, CH_2), 2.22 (m, 2 H, CH_2), 2.48 (s, 3 H, SCH_3), 3.68 (m, 2 H, 5'-H), 3.95 (m, 1 H, 4'-H), 4.03 (m, 1 H, 3'-H), 4.13 (q, 1 H, $J = 5.1$, 2'-H), 5.21 (m, 2 H, 3'-OH, 5'-OH), 5.56 (d, 1 H, $J = 5.7$, 2'-OH), 5.69 (d, 1 H, $J = 5.3$, 1'-H), 7.99 (s, 1 H, 6-H)	13.49 (CH_3), 14.08 (SCH_3), 20.30 (CH_2), 29.26 (CH_2), 60.57 (C-5'), 69.89 (C-3'), 74.61 (C-2'), 85.73 (C-4'), 91.37 (C-1'), 120.86 (C-5), 135.08 (C-6), 160.74 (C-2), 167.09 (C-4)
3e	2.47 (s, 3 H, SCH_3), 3.58 (m, 4 H, CH_2 , 5'-H), 3.94 (m, 1 H, 4'-H), 4.00 (m, 1 H, 3'-H), 4.10 (m, 1 H, 2'-H), 5.21 (br s, 2 H, 3'-OH, 5'-OH), 5.61 (br s, 1 H, 2'-OH), 5.68 (d, 1 H, $J = 5.0$, 1'-H), 7.23 (m, 5 H, H_{arom}), 8.09 (s, 1 H, 6-H)	14.14 (SCH_3), 33.14 (CH_2), 60.62 (C-5'), 69.83 (C-3'), 74.57 (C-2'), 85.72 (C-4'), 91.44 (C-1'), 120.54 (C-5), 125.89, 128.08, 128.35, 139.43 (C_{arom}), 136.16 (C-6), 161.19 (C-2), 166.71 (C-4)
3f	1.28 (t, 3 H, $J = 7.5$, SCH_2CH_3), 1.82 (s, 3 H, 5- CH_3), 3.13 (q, 2 H, $J = 7.5$, SCH_2), 3.63 (m, 2 H, 5'-H), 3.92 (q, 1 H, $J = 3.1$, 4'-H), 4.02 (q, 1 H, $J = 3.7$, 3'-H), 4.12 (q, 1 H, $J = 5.3$, 2'-H), 5.20 (m, 2 H, 3'-OH, 5'-OH), 5.53 (d, 1 H, $J = 5.8$, 2'-OH), 5.67 (d, 1 H, $J = 5.5$, 1'-H), 7.99 (s, 1 H, 6-H)	13.43 (5- CH_3), 13.97 (CH_3), 25.50 (SCH_2), 60.67 (C-5'), 69.85 (C-3'), 74.28 (C-2'), 85.73 (C-4'), 91.11 (C-1'), 117.28 (C-5), 135.37 (C-6), 160.48 (C-2), 167.59 (C-4)
3g	1.28 (t, 3 H, $J = 7.3$, SCH_2CH_3), 3.13 (q, 2 H, $J = 7.3$, SCH_2), 3.61 (s, 3 H, OCH_3), 3.67 (m, 2 H, 5'-H), 3.97 (m, 1 H, 4'-H), 4.06 (m, 1 H, 3'-H), 4.16 (m, 1 H, 2'-H), 5.21 (m, 1 H, 3'-OH), 5.37 (m, 1 H, 5'-OH), 5.56 (m, 1 H, 2'-OH), 5.73 (d, 1 H, $J = 4.8$, 1'-H), 7.94 (s, 1 H, 6-H)	14.06 (SCH_2CH_3), 25.65 (SCH_2), 55.66 (OCH_3), 60.22 (C-5'), 69.73 (C-3'), 74.84 (C-2'), 85.62 (C-4'), 91.91 (C-1'), 118.17 (C-5), 142.04 (C-6), 156.54 (C-2), 162.08 (C-4)

ylthio group was also a concomitant reaction during deprotection of **2h**. When **2i** was deprotected, it was not possible to detect the corresponding O^2 -methyl derivative. The substitution reaction was followed by a demethylation reaction of the methoxy group affording 5-cyanouridine **7** in 11% yield. Also hydrolysis by water present in the methanol could explain the formation of compound **7**.

Replacement of the methylthio group during the deprotection reaction was not observed when 5-alkyl- or 5-methoxy substituents were present in the uracil ring, **2b–g**, because of their electron-donating effect which retards the aromatic nucleophilic substitution reaction.

The compounds **3a–e**, **4–7** were tested for their antiviral activity against herpes simplex virus (HSV-1) in Vero cells and against human immunodeficiency virus (HIV-1) in MT-4 cells, however, no activity was observed.

Anhyd MeCN was distilled from P_2O_5 followed by distillation from CaH_2 . All other solvents were used after distillation. Analytical silica gel TLC plates 60 F₂₅₄ and silica gel (230–400 mesh) were purchased from Merck. Optical rotations were measured with a Perkin-Elmer 141 polarimeter. NMR spectra were recorded on a Bruker AC 250 FT NMR spectrometer at 250 MHz for ^1H NMR and 62.9 MHz for ^{13}C NMR with TMS as an internal standard. EI mass spectra were obtained on a Varian MAT 311 A spectrometer. FAB mass spectra were recorded on a Kratos MS-50 spectrometer.



Scheme 3

Preparation of 2-Ethylthiopyrimidin-4(1H)-ones **1f, g**; General Procedure:

A solution of substituted 2-thiouracils (0.1 mol), EtI (0.1 mol) and 1 M aq NaOH (100 mL) and EtOH (200 mL) was stirred at 60°C overnight. Half of the EtOH was evaporated off and the mixture allowed to cool. The solid was collected, dried and recrystallized from EtOH.

2-Ethylthio-5-methylpyrimidin-4(1H)-one (1f); yield: 72%; colorless needles; mp 158°C.

$\text{C}_7\text{H}_{10}\text{N}_2\text{OS}$ calc. C 49.39 H 5.92 N 16.45
(170.2) found 49.16 5.92 16.24

$^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ = 1.28 (t, 3 H, J = 7.5 Hz, SCH_2CH_3), 1.87 (s, 3 H, 5- CH_3), 3.07 (q, 2 H, J = 7.5 Hz, SCH_2CH_3), 7.72 (s, 1 H, 6-H), 12.56 (s, 1 H, NH).

$^{13}\text{C NMR}$ ($\text{DMSO}-d_6$): δ = 12.29 (5- CH_3), 14.37 (CH_2CH_3), 23.95 (CH_2CH_3), 118.74 (C-5), 150.27 (C-6), 158.73 (C-4), 162.89 (C-2).

2-Ethylthio-5-methoxypyrimidine-4(1H)-one (1g); yield: 68%; colorless needles; mp > 300°C.

$\text{C}_7\text{H}_{10}\text{N}_2\text{O}_2\text{S}$ calc. C 45.14 H 5.41 N 15.04
(176.2) found 45.01 5.39 14.98

$^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ = 1.29 (t, 3 H, J = 7.5 Hz, SCH_2CH_3), 3.07 (q, 2 H, J = 7.5 Hz, SCH_2CH_3), 3.70 (s, 3 H, OCH_3), 7.52 (s, 1 H, 6-H).

$^{13}\text{C NMR}$ ($\text{DMSO}-d_6$): δ = 14.42 (CH_2CH_3), 24.25 (CH_2CH_3), 56.10 (OCH_3), 130.54 (C-5), 143.55 (C-6), 151.23 (C-4), 157.87 (C-2).

Preparation of **2a-i**; General Procedure:

2-Alkylthiopyrimidin-4(1H)-one derivatives **1a-i** (8 mmol) were treated with 1,1,1,3,3,3-hexamethyldisilazane (30 mL) and $(\text{NH}_4)_2\text{SO}_4$ (50 mg) at reflux for 1 h (clear solution after 0.5 h). The solvent was removed in vacuo. The residue was dissolved in anhyd MeCN (20 mL) and 1,2,3,5-tetra-*O*-acetyl- β -D-ribofuranose (1.71 g, 5.4 mmol) was added. The reaction mixture was cooled to -30°C. A solution of $\text{CF}_3\text{SO}_3\text{SiMe}_3$ (1.3 mL, 6.5 mmol) in anhyd MeCN (5 mL) was added dropwise with stirring. The mixture was stirred for 0.5 h at -25°C and then at r.t. for 0.5 h. The mixture was diluted with CH_2Cl_2 (200 mL) and extracted with ice-cold sat. aq

NaHCO_3 . The organic phase was separated, washed with cold H_2O (3×150 mL), and dried (Na_2SO_4). The solvent was evaporated in vacuo to obtain the crude products which were chromatographed on a silica gel column using 5–8% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ as eluent.

Preparation of **3-7**; General Procedure:

Sat. NH_3 in MeOH (40 mL) was added with stirring to a solution of **2a-i** (2–5 mmol) in MeOH (20 mL) at 0°C. The mixture was stirred at r.t. for 1 h and the solvent was evaporated in vacuo. The residue was chromatographed on a silica gel column with 5% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ to give the products **3-7**. Compound **2a** (1.0 g, 2 mmol) was also treated with MeONa (2.2 mmol) in MeOH (30 mL) at 0°C and stirring at r.t. for 1 h. After neutralization with NH_4Cl (120 mg, 2.3 mmol), the solvent was removed in vacuo and the residue was chromatographed on a silica gel column with 7% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ to give **4** in 43% yield.

O²-Methyluridine (4); yield: 0.43 g (34%); mp 172–173°C (Lit.^{13–15} mp 173°C); $[\alpha]_D^{25} + 35.45$ (c = 1, H_2O).

Ethyl O²-Methyluridine-5-carboxylate (5); yield: 200 mg (19%); foam.

HRMS: $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_8$, calc. 330.1063; found 330.1069.

$^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ = 1.24 (t, 3 H, J = 7.0 Hz, CH_3), 3.16 (s, 3 H, OCH_3), 3.60 (dd, 1 H, J = 12.0, 2.2 Hz, 5'-H), 3.73 (dd, 1 H, J = 12.0, 2.2 Hz, 5'-H), 3.92 (m, 1 H, 4'-H), 3.99 (t, 1 H, J = 4.6 Hz, 3'-H), 4.07 (t, 1 H, J = 3.6 Hz, 2'-H), 4.16 (q, 2 H, J = 7.1 Hz, OCH_2), 5.15 (br s, 3 H, 2'-OH, 3'-OH, 5'-OH), 5.80 (d, 1 H, J = 3.2 Hz, 1'-H), 8.94 (s, 1 H, 6-H).

$^{13}\text{C NMR}$ ($\text{DMSO}-d_6$): δ = 13.93 (CH_3), 55.78 (OCH_3), 59.80, 59.96 (OCH_2 , C-5'), 68.91 (C-3'), 74.58 (C-2'), 84.91 (C-4'), 90.49 (C-1'), 110.38 (C-5), 144.03 (C-6), 162.19 (C-2), 163.26 (C-4), 164.92 (COOEt).

MS EI: m/z (%) = 330 (M^+ , 4).

O²-Methyluridine-5-carboxamide (6); yield: 150 mg (15%); mp 174–176°C.

HRMS: $\text{C}_{11}\text{H}_{15}\text{N}_3\text{O}_7$ calc. C 301.091; found 301.090.

$^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ = 3.62 (m, 2 H, 5'-H), 3.96 (m, 5 H, OCH_3 , 3'-H, 4'-H), 4.13 (br s, 1 H, 2'-H), 5.11 (m, 2 H, 3'-OH, 5'-OH), 5.53 (br s, 1 H, 2'-OH), 5.76 (d, 1 H, J = 4.5 Hz, 1'-H), 7.50 (s, 1 H, 6-H), 8.82 (s, 2 H, NH_2).

$^{13}\text{C NMR}$ ($\text{DMSO}-d_6$): δ = 56.11 (OCH_3), 60.52 (C-5'), 69.52 (C-3'), 74.38 (C-2'), 85.35 (C-4'), 90.40 (C-1'), 111.30 (C-5), 143.74 (C-6), 155.42 (C-2), 163.69 (C-4), 168.95 (CO).

MS EI: m/z (%) = 301 (M^+ , 0.7).

Uridine-5-carbonitrile (7); yield: 151 mg (11%); mp 188–190°C (Lit.^{16–18}, mp 191–192°C).

- (1) Singer, B.; Fraenkel-Conrat, H.; Kusmierek, J. T. *Proc. Nat. Acad. Sci. U.S.A.* **1978**, *75*, 1722.
- (2) Singer, B.; Fraenkel-Conrat, H. *Biochemistry* **1975**, *14*, 772.
- (3) Sun, L.; Singer, B. *Biochemistry* **1975**, *14*, 1795.
- (4) Singer, B.; Kusmierek, J. T. *Biochemistry* **1976**, *15*, 5052.
- (5) Singer, B. *Nature (London)* **1976**, *264*, 333.
- (6) Singer, B. *J. Toxicol. Environ. Health* **1977**, *2*, 1279.
- (7) Ogihara, T.; Mitsunobu, O. *Chem. Lett.* **1982**, 1621.
- (8) Sato, E.; Machida, M.; Kanaoka, Y. *Chem. Pharm. Bull.* **1980**, *28*, 1722.
- (9) Vorbrüggen, H.; Krolkiewicz, K. *Angew. Chem.* **1976**, *88*, 724.
- (10) Brown, T. H.; Blakemore, R. C.; Durant, G. J.; Emmett, J. C.; Ganellin, C. R.; Parsons, M. E.; Rawlings, D. A.; Walker, T. F. *Eur. J. Med. Chem.* **1988**, *23*, 53.
- (11) Wittenburg, E. *Z. Chem.* **1964**, *4*, 303.
- (12) Vorbrüggen, H.; Krolkiewicz, K.; Bennua, B. *Chem. Ber.* **1981**, *114*, 1234.

- (13) Brown, D. M.; Todd, Sir A. R.; Varadarajan, S. *J. Chem. Soc.* **1957**, 868.
- (14) Kimura, J.; Fujisawa, Y.; Yoshizawa, T.; Fukuda, K.; Mitsunobu, O. *Bull. Chem. Soc. Jpn.* **1979**, 52, 1191.
- (15) Kimura, J.; Yagi, K.; Suzuki, H.; Mitsunobu, O. *Bull. Chem. Soc. Jpn.* **1980**, 53, 3670.
- (16) Prystas, M.; Sorm, F. *Coll. Czech. Chem. Commun.* **1966**, 31, 3990.
- (17) Torrence, P. F.; Bhooshan, B.; Descamps, J.; De Clercq, E. *J. Med. Chem.* **1977**, 20, 974.
- (18) Inoue, H.; Ueda, T. *Chem. Pharm. Bull.* **1978**, 26, 2657.